372948-28-2
Chemical Structure
RAPTA-C
Synonym(s): Ru(η6-p-cymene)Cl2(pta)
- CAS No.: 372948-28-2
- Formula:C16H23Cl2N3PRu
- Molecular Weight:460.32
InChIKey: LPKFTBOBUFTCMA-UHFFFAOYSA-M
SMILES: CC12=C3[Ru+2]145(C6=C52)(P78C[N@@](C9)C[N@@](C[N@@]9C8)C7)([Cl-])([Cl-])C6(C(C)C)=C43
Biological Activity: RAPTA-C is a ruthenium-based antimetastatic agent. RAPTA-C binds chromatin histones and interacts with DNA, leading to pH-dependent DNA damage and hypoxia selectivity. RAPTA-C inhibits angiogenesis, microvessel density, tumor growth, invasion, and proliferation, and induces apoptosis through the mitochondrial pathway, G2/M phase arrest, quiescence, and vascular normalization. RAPTA-C can be used in research on ovarian cancer, colorectal adenocarcinoma, breast cancer metastasis, and Ehrlich ascites carcinoma[1][2][3][4][5][6][7][8][9][10].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
RAPTA-C | 99.30% | RAPTA-C is a ruthenium-based antimetastatic agent. RAPTA-C binds chromatin histones and interacts with DNA, leading to pH-dependent DNA damage and hypoxia selectivity. RAPTA-C inhibits angiogenesis, microvessel density, tumor growth, invasion, and proliferation, and induces apoptosis through the mitochondrial pathway, G2/M phase arrest, quiescence, and vascular normalization. RAPTA-C can be used in research on ovarian cancer, colorectal adenocarcinoma, breast cancer metastasis, and Ehrlich ascites carcinoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Berndsen RH, et al. Combination of ruthenium(II)-arene complex [Ru(η-p-cymene)Cl(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity. Scientific reports. 2017 Feb 22;7:43005.
- [2]. Lu M, et al. A new 3D organotypic model of ovarian cancer to help evaluate the antimetastatic activity of RAPTA-C conjugated micelles. Biomaterials science. 2019 Mar 26;7(4):1652-1660.
- [3]. Groessl M, et al. CZE-ICP-MS as a tool for studying the hydrolysis of ruthenium anticancer drug candidates and their reactivity towards the DNA model compound dGMP. Journal of inorganic biochemistry. 2008;102(5-6):1060-5.
- [4]. Scolaro C, et al. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes. Journal of medicinal chemistry. 2005 Jun 16;48(12):4161-71.
- [5]. Weiss A, et al. In vivo anti-tumor activity of the organometallic ruthenium (II)-arene complex [Ru (η6-p-cymene) Cl2 (pta)](RAPTA-C) in human ovarian and colorectal carcinomas. Chemical Science. 2014 Oct 28;5(12):4742-8.
- [6]. Nowak-Sliwinska P, et al. Organometallic ruthenium (II) arene compounds with antiangiogenic activity. Journal of medicinal chemistry. 2011 Jun 9;54(11):3895-902.
- [7]. Lu H, et al. Anti-metastatic effects of RAPTA-C conjugated polymeric micelles on two-dimensional (2D) breast tumor cells and three-dimensional (3D) multicellular tumor spheroids. Acta biomaterialia. 2016 Mar 01;32:68-76.
- [8]. Nowak-Sliwinska P, et al. Antiangiogenic and Anticancer Properties of Bifunctional Ruthenium(II)-p-Cymene Complexes: Influence of Pendant Perfluorous Chains. Molecular pharmaceutics. 2015 Aug 03;12(8):3089-96.
- [9]. Clavel CM, et al. Modulating the Anticancer Activity of Ruthenium(II)-Arene Complexes. Journal of medicinal chemistry. 2015 Apr 23;58(8):3356-65.
- [10]. Chatterjee S, et al. The ruthenium(II)-arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways. Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry. 2008 Sep;13(7):1149-55. [Content Brief]
